Вид доставки
Доставка почтовыми службами, Доставим, Другое, Международная доставка
https://www.astersteroids.com/triple-receptor-agonist-peptides-retatrutide-ly-3437943-benefits-in-weight-loss/
Purity:98% HPLC
Packing:2mg/vial and 5mg/vial;10vials/box
Min Order: 1box
Payment:Bitcoin,Moneygram and Wester Union
Lead time:24hours after received payment
Safe shipping to US and most of Europe country
Storage:Shading, confined preservation,2-8°C
Retatrutide, number LY-3437943, is arguably the latest promising drug for weight loss and the treatment of type 2 diabetes in obese/overweight patients. It has a completely new mode of action, and clinical trials have shown that it is more effective in weight loss than the FDA-approved Semagelutide(Wegovy) and Tirzepatide(Mounjaro). Perhaps you have not heard of this new weight loss peptide, today we will introduce it -Retatrutide.
What is peptides Retatrutide LY-3437943?
For sale Retatrutide LY-3437943 basic information:
Cas No.:2381089-83-2
MF:C223H343F3N46O70
MW: 4845.444
Some approved weight loss products were originally developed to treat type 2 diabetes and work based on things like appetite control and delayed gastric empting. Retatrutide, a new drug in development for the treatment of obesity, is a triple receptor agonist that activates the GLP-1(glucagon-like peptide-1) receptor,GIP(Glucose-dependent insulin stimulating) receptor and GCGR (glucagon) receptors in the body, an unprecedented way to lose weight.
How does Retatrutide lose weight?
A preliminary understanding of how Retatrutide works for weight loss can be found in the three receptors it acts on.
GLP-1: Glucagon-like peptide 1
GLP-1 is the key word in the treatment of type 2 diabetes, which mainly plays a role in regulating blood sugar in the body. it inhibits appetite and slows stomach emptying, helping to lower blood sugar while also helping with weight loss, which is why drugs used to treat type 2 diabetes can also be used for weight loss.
GIP: Glucose-dependent insulin-promoting polypeptide
GIP, also known as gastric inhibitory peptides, reduces hunger and increases satiety by reducing the secretion of stomach acid and the speed at which food is transported through the stomach.
Compared with single GLP-1 agonists, GLP-1 and GIP dual agonists increase overall energy expenditure and reduce caloric intake, thus achieving better weight loss. This is the mode of action of Tirzepatide, a new type 2 diabetes drug developed by Eli Lilly and Co., which is a double receptor agonist for GLP-1 and GIP, and is a completely new attempt. Its effectiveness has been proven and it has been approved by the FDA. Tirzepatide’s weight loss was equally impressive, showing an average weight loss of 22.5 percent (about 52 pounds) after 72 weeks of use, while Semaglutide experienced an average weight loss of about 15 percent (34 pounds) after 68 weeks.
Retatrutide is another Lilly innovation that has a completely new mode of action, activating GCG(glucagon) receptors in addition to GLP-1 receptors and GIP receptors.
What is GCG(Glucagon)?
GCG ,is glucagon, acts as the opposite of insulin, which reduces glucose levels outside the cell. So how does Retatrutide’s activation of glucagon receptors play a role in weight loss?
Glucagon promotes glycogen breakdown, converting stored glycogen into glucose, which is then released into the bloodstream to provide energy for the body. This pattern increases blood sugar to a certain extent, but it also promotes lipolysis and enhances the oxidation of fatty acids, converting them into usable energy for the body. Glucagon also reduces the synthesis of fatty acids in fat tissue and liver, and promotes lipolysis in these tissues, providing an energy source for tissues such as skeletal muscle.
Therefore, compared with the hypoglycemic effects of GLP-1 and GIP, glucagon is more conducive to reducing fat, breaking down fat, and promoting metabolism. Retatrutide acts as a GLP-1,GIP, and glucagon triple receptor agonist with better weight loss results. Clinical trials showed that obese, overweight patients experienced an average weight loss of 24.2 percent (about 57.8 pounds or 26.2kg) after 48 weeks of use of Retatrutide. This is another milestone for any weight-loss drug, so even though Retatrutide has just completed Phase II clinical trials, it is already attracting a lot of attention.
